Predict your next investment

HEALTHCARE | Biotechnology
bayhilltherapeutics.com

See what CB Insights has to offer

Founded Year

2000

Stage

Dead | Dead

Total Raised

$97.35M

About Bayhill Therapeutics

Bayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill's BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without effecting normal protective immune system cells. BHT-DNA is being studied in a Phase II trial for multiple sclerosis and a Phase I/II trial for autoimmune diabetes. Bayhill's second therapeutic is an oligonucleotide in preclinical development for systemic lupus erythematosus.

Bayhill Therapeutics Headquarter Location

1810 Gateway Drive Suite 150

San Mateo, California, 94404,

United States

650-320-2800

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bayhill Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bayhill Therapeutics is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,750 items

Bayhill Therapeutics Patents

Bayhill Therapeutics has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/21/2003

10/12/2010

Cannabinoids, Inflammations, Designer drugs, Indoles, Clusters of differentiation

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/21/2003

00/00/0000

Grant Date

10/12/2010

00/00/0000

Title

Subscribe to see more

Related Topics

Cannabinoids, Inflammations, Designer drugs, Indoles, Clusters of differentiation

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.